Our Pricing

Published on: June 03, 2026

When you buy weight loss injections UK online from Cured Pharmacy, you access genuine MHRA-licensed treatments including Mounjaro, Wegovy, and Saxenda with transparent upfront pricing and free clinical assessment by UK prescribers. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets the highest regulatory standards, with discreet delivery across the UK.

How GLP-1 Weight Loss Injections Work

GLP-1 receptor agonists represent the most clinically effective weight loss medications licensed in the UK by the MHRA. These injections mimic glucagon-like peptide-1, a naturally occurring hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity [1]. Unlike traditional weight loss tablets, GLP-1 treatments target multiple metabolic pathways simultaneously.

Mounjaro (tirzepatide) advances this mechanism further as the UK's first dual GIP/GLP-1 receptor agonist, activating both glucose-dependent insulinotropic polypeptide and GLP-1 pathways [2]. In the SURPASS-2 trial, participants achieved an average 22.5% body weight reduction over 72 weeks on the 15mg dose — significantly superior to single-pathway alternatives [2].

Wegovy (semaglutide) and Saxenda (liraglutide) work through selective GLP-1 activation. The STEP-1 trial demonstrated that semaglutide 2.4mg produced an average 14.9% weight loss over 68 weeks, whilst liraglutide 3mg achieved approximately 8% reduction in the SCALE trial [1][3]. All three treatments require subcutaneous injection and are available only by prescription following clinical assessment by a UK prescriber.

Comparing Weight Loss Injections: Mounjaro, Wegovy & Saxenda

Choosing between Mounjaro, Wegovy, and Saxenda depends on your clinical profile, weight loss goals, and tolerance for injection frequency. Mounjaro delivers the highest average weight reduction in clinical trials but requires weekly injections and carries a higher initial cost at £135.00. Wegovy offers strong efficacy with once-weekly dosing from £135.00 making it a popular middle-ground option for many UK patients.

Saxenda requires daily injections but starts from £10 offering the most accessible entry point for prescription weight loss treatment. The daily dosing schedule may suit patients who prefer gradual dose escalation or have concerns about once-weekly injectable volumes. Your UK prescriber will evaluate your BMI, medical history, previous weight loss attempts, and any contraindications during your free online consultation.

All three medications are MHRA-licensed for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity such as hypertension or type 2 diabetes [4]. Treatment effectiveness improves significantly when combined with a reduced-calorie diet and increased physical activity, as demonstrated across all major clinical trials [1][2][3].

Weekly vs Daily Injections: Practical Considerations

Weekly injections (Mounjaro, Wegovy) use pre-filled pens that deliver a precise dose with a single administration, which many patients find more convenient for maintaining long-term adherence. Daily injections (Saxenda) require more frequent administration but allow finer dose titration during the initial escalation phase, potentially reducing gastrointestinal side effects in sensitive individuals.

Clinical Evidence: What the Trials Show

The SURPASS clinical trial programme evaluated tirzepatide across multiple doses and patient populations. SURPASS-2 compared tirzepatide directly against semaglutide 1mg in adults with type 2 diabetes, demonstrating superior weight reduction: participants on tirzepatide 15mg lost an average of 13.1kg compared to 7.9kg with semaglutide over 40 weeks [2]. The weight loss continued in longer trials, with SURPASS-3 showing sustained reductions beyond 72 weeks.

Semaglutide's efficacy is established through the STEP trial series. STEP-1 enrolled 1,961 adults without diabetes, achieving a mean weight loss of 14.9% (15.3kg) on semaglutide 2.4mg versus 2.4% (2.6kg) on placebo over 68 weeks [1]. Importantly, 86.4% of semaglutide participants achieved at least 5% weight loss, and 69.1% achieved at least 15% reduction — thresholds associated with meaningful metabolic improvements.

Liraglutide 3mg demonstrated consistent but more modest results in the SCALE trials. The SCALE Obesity and Prediabetes trial showed mean weight loss of 8.0% versus 2.6% with placebo over 56 weeks, with 63.2% of liraglutide participants achieving at least 5% weight reduction [3]. All trials required lifestyle modification alongside medication, and all three treatments are subject to prescriber approval based on individual clinical assessment.

Real-World Effectiveness vs Clinical Trials

Clinical trial conditions include intensive dietary counselling, regular monitoring, and carefully selected participants, which may not fully reflect real-world outcomes. UK prescribers emphasise that individual results vary based on adherence, baseline metabolic health, concurrent medications, and lifestyle factors. Maintaining weight loss typically requires ongoing treatment, as discontinuation often leads to weight regain [4].

Common Side Effects and How to Manage Them

Gastrointestinal side effects are the most frequently reported adverse events across all GLP-1 treatments. Nausea affects approximately 44% of Wegovy users, 40% of Mounjaro users, and 39% of Saxenda users during dose escalation, though symptoms typically diminish over 4-8 weeks as the body adapts [1][2][3]. Vomiting, diarrhoea, constipation, and abdominal discomfort occur less frequently but follow similar patterns.

Your UK prescriber will initiate treatment at the lowest therapeutic dose and gradually increase over several weeks to minimise gastrointestinal symptoms. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce nausea severity. If side effects become intolerable, your prescriber may slow the escalation schedule or adjust your dose.

Rare but serious side effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking concurrent diabetes medications). GLP-1 treatments carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [4]. All prescription weight loss injections require ongoing monitoring by a UK healthcare professional.

Who Can Use Weight Loss Injections in the UK

MHRA licensing criteria specify that GLP-1 weight loss injections are indicated for adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, dyslipidaemia, obstructive sleep apnoea, or type 2 diabetes [4]. Your UK prescriber will calculate your BMI and review your complete medical history during the online consultation.

These treatments are not suitable for everyone. Contraindications include pregnancy or breastfeeding, personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, severe gastrointestinal disease, and diabetic ketoacidosis. Patients with a history of pancreatitis, severe renal impairment, or eating disorders require particularly careful evaluation before prescription approval.

At Cured Pharmacy, every prescription requires clinical assessment by a UK-registered prescriber who evaluates your eligibility, reviews potential drug interactions, and ensures the treatment aligns with NICE guidance on weight management. The consultation takes under 3 minutes to complete online, and our clinical team will contact you if additional information is needed before approving your prescription.

Age and Special Populations

Weight loss injections are licensed for adults aged 18 and over. Use in patients over 75 years requires additional caution due to limited clinical trial data in this age group. Adolescents aged 12-17 may be eligible for specific formulations under specialist supervision, but this falls outside standard online pharmacy prescribing pathways and requires face-to-face specialist assessment.

How to Buy Weight Loss Injections UK Online Safely

When you buy weight loss injections UK online, verification of pharmacy credentials protects you from counterfeit medications and unregulated suppliers. Cured Pharmacy operates under GPhC registration number 9012511, with superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing all clinical services. You can verify our registration on the General Pharmaceutical Council website at any time.

Our process begins with a free online consultation that takes under 3 minutes. You'll answer questions about your weight history, current medications, medical conditions, and weight loss goals. A UK-registered prescriber reviews your assessment the same day, and if approved, your prescription is dispensed from our UK pharmacy with discreet packaging and next-day delivery options available.

Beware of websites offering weight loss injections without prescription, at prices significantly below market rates, or shipped from non-UK sources. Counterfeit semaglutide and tirzepatide products have been identified by the MHRA, some containing incorrect doses or no active ingredient at all. Genuine UK-licensed medications carry specific batch numbers, patient information leaflets, and tamper-evident packaging that you should verify upon receipt.

Transparent Pricing at Cured Pharmacy

Unlike many online pharmacies, we display exact prices before you begin your consultation. Mounjaro starts from £135.00 Wegovy from £135.00 and Saxenda from £135.00 with no hidden fees or subscription requirements. Your final price depends on the dose your prescriber determines is clinically appropriate, and you'll see the complete cost breakdown before confirming your order.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, dietary modification, and lifestyle factors. Cured Pharmacy operates under GPhC registration 9012511 with superintendent pharmacist Tarun Kumar (GPhC 2233073).